HIGHLIGHTS
- who: E. Van Cutsem from the University Hospitals, Gdynia, Poland have published the research work: First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study, in the Journal: (JOURNAL) of 28/07/2021
- what: The aim of this article is to present the final OS analysis of the TASCO1 trial, performed after the last patient had withdrawn from the study. The trial was not designed to confirm a statistical difference between study treatments, and was therefore considered non-comparative. The phase II TASCO1 trial was designed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.